BRPI0813680A8 - composição compreendendo um agente de irna para alfa-enac, constituído por um fita senso e uma fita antissenso, e seu uso - Google Patents

composição compreendendo um agente de irna para alfa-enac, constituído por um fita senso e uma fita antissenso, e seu uso Download PDF

Info

Publication number
BRPI0813680A8
BRPI0813680A8 BRPI0813680A BRPI0813680A BRPI0813680A8 BR PI0813680 A8 BRPI0813680 A8 BR PI0813680A8 BR PI0813680 A BRPI0813680 A BR PI0813680A BR PI0813680 A BRPI0813680 A BR PI0813680A BR PI0813680 A8 BRPI0813680 A8 BR PI0813680A8
Authority
BR
Brazil
Prior art keywords
tape
alpha
composition
irna agent
agent consisting
Prior art date
Application number
BRPI0813680A
Other languages
English (en)
Portuguese (pt)
Inventor
Geick Anke
Hickman Emma
Van Heeke Gino
Vornlocher Hans-Peter
Luke Danahay Henry
Tan Pamela
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0813680A2 publication Critical patent/BRPI0813680A2/pt
Publication of BRPI0813680B1 publication Critical patent/BRPI0813680B1/pt
Publication of BRPI0813680A8 publication Critical patent/BRPI0813680A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0813680A 2007-06-15 2008-06-13 composição compreendendo um agente de irna para alfa-enac, constituído por um fita senso e uma fita antissenso, e seu uso BRPI0813680A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07110376 2007-06-15
EP07110376.6 2007-06-15
EP07114265 2007-08-13
EP07114265.7 2007-08-13
PCT/EP2008/057476 WO2008152131A2 (en) 2007-06-15 2008-06-13 Rnai inhibition of alpha-enac expression

Publications (3)

Publication Number Publication Date
BRPI0813680A2 BRPI0813680A2 (pt) 2015-01-06
BRPI0813680B1 BRPI0813680B1 (pt) 2018-02-06
BRPI0813680A8 true BRPI0813680A8 (pt) 2018-08-28

Family

ID=40130244

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813680A BRPI0813680A8 (pt) 2007-06-15 2008-06-13 composição compreendendo um agente de irna para alfa-enac, constituído por um fita senso e uma fita antissenso, e seu uso

Country Status (26)

Country Link
US (12) US7718632B2 (enExample)
EP (7) EP2224005B1 (enExample)
JP (6) JP5485146B2 (enExample)
KR (2) KR101821081B1 (enExample)
CN (1) CN101778941B (enExample)
AR (1) AR066984A1 (enExample)
AU (1) AU2008263876B2 (enExample)
BR (1) BRPI0813680A8 (enExample)
CA (1) CA2690674C (enExample)
CL (1) CL2008001756A1 (enExample)
CO (1) CO6251331A2 (enExample)
CR (1) CR11136A (enExample)
CU (1) CU23774A3 (enExample)
EA (1) EA200901653A1 (enExample)
EC (1) ECSP099794A (enExample)
ES (6) ES2432644T3 (enExample)
GT (1) GT200900315A (enExample)
IL (1) IL202366A0 (enExample)
MA (1) MA31564B1 (enExample)
MX (1) MX2009013609A (enExample)
PE (1) PE20090942A1 (enExample)
SG (3) SG169988A1 (enExample)
SV (1) SV2009003434A (enExample)
TN (1) TN2009000521A1 (enExample)
TW (3) TWI552753B (enExample)
WO (1) WO2008152131A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2322145T3 (es) * 2002-07-26 2009-06-17 Novartis Vaccines And Diagnostics, Inc. Moleculas pequeñas modificadas de adn inerferente y procedimiento de uso.
KR100473148B1 (ko) * 2002-11-27 2005-03-10 (주)텔리언 버스트모드 패킷 전달을 위한 정합장치 및 방법
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
JP2008514242A (ja) * 2004-10-01 2008-05-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 改変型の小さい干渉ｒｎａ分子および使用方法
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
KR20110095391A (ko) * 2008-11-26 2011-08-24 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 상피 나트륨 채널 (ＥＮａＣ) 유전자 발현의 ＲＮＡ 간섭 매개 억제
EP2756845B1 (en) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
CN103275978B (zh) * 2009-04-03 2014-10-29 百奥迈科生物技术有限公司 修饰的小干扰核酸及其制备方法
WO2010111891A1 (zh) * 2009-04-03 2010-10-07 北京大学 修饰的寡聚核酸分子及其制备方法和应用
US20120207818A1 (en) * 2009-07-14 2012-08-16 Shinohara Fumikazu Composition for suppressing expression of target gene
DK3252068T3 (da) * 2009-10-12 2025-08-25 Larry J Smith Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
MX339050B (es) 2009-12-18 2016-05-09 Novartis Ag Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
EP3061824B1 (en) * 2010-04-23 2018-08-29 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-enac-related diseases
CN103703141B (zh) * 2011-04-08 2016-08-17 伯乐实验室公司 具有降低的非特异性活性的pcr反应混合物
EP2699271A4 (en) 2011-04-20 2015-10-07 Larry J Smith METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING COMPONENTS THAT SELF-ASSEMBLED IN CELLS AND PRODUCE RNAI ACTIVITY
EP3693464A3 (en) * 2011-06-21 2020-12-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
WO2013030778A2 (en) 2011-09-02 2013-03-07 Novartis Ag Organic compositions to treat hsf1-related diseases
JP7291624B2 (ja) 2016-11-01 2023-06-15 アローヘッド ファーマシューティカルズ インコーポレイテッド アルファ－ｖベータ－６インテグリンリガンド及びその使用
KR20200024793A (ko) * 2017-07-06 2020-03-09 애로우헤드 파마슈티컬스 인코포레이티드 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
CA3074739A1 (en) * 2017-10-31 2019-05-09 Ionis Pharmaceuticals, Inc. Modulators of enac expression
BR112020006901A2 (pt) * 2017-11-01 2020-10-13 Arrowhead Pharmaceuticals, Inc. ligantes de integrina e usos dos mesmos
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
EP4021413A4 (en) * 2019-08-30 2023-07-05 United States Government as Represented by The Department of Veterans Affairs LIPOSOMAL TROPONOID COMBINATION FORMULATIONS
US12415840B2 (en) 2020-02-21 2025-09-16 Brookhaven Science Associates, Llc Modified form of oleosin that when expressed in plants leads to increased triacylglycerol (oil) accumulation
EP4319765A1 (en) 2021-04-08 2024-02-14 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
US11957178B2 (en) 2021-11-15 2024-04-16 Apackaging Group Llc Aerosol actuator

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
DE3604625C2 (de) * 1986-02-14 1994-01-20 Bmw Rolls Royce Gmbh Gasturbine
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5451670A (en) * 1987-12-09 1995-09-19 City Of Hope Restriction fragment length polymorphism test for haplotyping domesticated fowl
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013566A (en) * 1988-12-19 1991-05-07 Sampson Michael James Process for obtaining improved yields from plants used for hay making by using a coating agent
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5665710A (en) * 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
RU2123492C1 (ru) * 1993-02-19 1998-12-20 Ниппон Синяку Ко., Лтд Производные глицерина, средство для доставки физиологически активного вещества и фармацевтическая композиция
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
CA2137297C (en) * 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
JP3543347B2 (ja) * 1994-01-24 2004-07-14 日本油脂株式会社 点火薬造粒物の製造方法
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
DE69629702T2 (de) 1995-08-01 2004-06-17 Isis Pharmaceuticals, Inc., Carlsbad Liposomale oligonukleotidzusammensetzungen
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en) * 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US5865710A (en) * 1996-08-01 1999-02-02 Wilson-Hyde; Cynthia Step aerobic platform
WO1998040516A1 (en) 1997-03-11 1998-09-17 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
DE69834038D1 (de) * 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
EP1873259B1 (en) * 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
EP1399593A2 (en) 2001-05-16 2004-03-24 Novartis AG Genes expressed in breast cancer as prognostic and therapeutic targets
EP1478655A4 (en) 2001-12-31 2006-05-10 Algos Therapeutics Inc METHODS AND SUBSTANCES FOR ENAC-BETA MODULATION
ES2322145T3 (es) 2002-07-26 2009-06-17 Novartis Vaccines And Diagnostics, Inc. Moleculas pequeñas modificadas de adn inerferente y procedimiento de uso.
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
EP2314691A3 (en) * 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
AU2003293124A1 (en) 2002-11-27 2004-06-23 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
AU2002368410A1 (en) 2002-11-29 2004-06-23 Basf Aktiengesellschaft Methods for the production of methionine
DE10305213A1 (de) * 2003-02-07 2004-08-26 Florian Prof. Dr.med. Lang Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
US20050095225A1 (en) * 2003-03-31 2005-05-05 Engelhardt John F. Compounds and methods for pharmico-gene therapy of epithelial sodium channel associated disorders
US7723509B2 (en) * 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4530335B2 (ja) * 2004-02-03 2010-08-25 独立行政法人科学技術振興機構 膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬
CN101052717A (zh) * 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
SE0402832D0 (sv) * 2004-11-18 2004-11-18 Astrazeneca Ab Methods
US20060166234A1 (en) * 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
US7361752B2 (en) * 2004-12-14 2008-04-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of MLL-AF4 and uses thereof
EP1948674A4 (en) * 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
WO2007070509A2 (en) * 2005-12-13 2007-06-21 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Epithelial sodium channel inhibiting agents and uses therefor
KR101133799B1 (ko) 2006-08-18 2012-04-24 에프. 호프만-라 로슈 아게 폴리뉴클레오타이드의 생체내 전달을 위한 다가접합체
AU2007306542B2 (en) 2006-10-11 2013-08-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Influenza targets
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)

Also Published As

Publication number Publication date
CO6251331A2 (es) 2011-02-21
JP2022188234A (ja) 2022-12-20
CL2008001756A1 (es) 2009-02-20
US20220112505A1 (en) 2022-04-14
US7939508B2 (en) 2011-05-10
AU2008263876A1 (en) 2008-12-18
ES2432532T3 (es) 2013-12-04
IL202366A0 (en) 2011-08-01
TWI629063B (zh) 2018-07-11
CU23774A3 (es) 2012-02-15
MA31564B1 (fr) 2010-08-02
CA2690674A1 (en) 2008-12-18
ES2432643T3 (es) 2013-12-04
ES2439277T3 (es) 2014-01-22
EP2224004A1 (en) 2010-09-01
BRPI0813680B1 (pt) 2018-02-06
EP2223692B1 (en) 2013-07-24
JP6680728B2 (ja) 2020-04-15
US7718632B2 (en) 2010-05-18
JP5719047B2 (ja) 2015-05-13
ES2432157T3 (es) 2013-12-02
EP2223695B1 (en) 2013-07-24
KR101653008B1 (ko) 2016-08-31
JP2020094063A (ja) 2020-06-18
EP2223692A1 (en) 2010-09-01
JP5485146B2 (ja) 2014-05-07
TW200911989A (en) 2009-03-16
WO2008152131A2 (en) 2008-12-18
TW201636027A (zh) 2016-10-16
US20100190714A1 (en) 2010-07-29
SV2009003434A (es) 2011-03-23
JP2017222704A (ja) 2017-12-21
US9914927B2 (en) 2018-03-13
CR11136A (es) 2010-01-20
PE20090942A1 (es) 2009-08-05
JP2014129373A (ja) 2014-07-10
US9074212B2 (en) 2015-07-07
US20100216972A1 (en) 2010-08-26
TN2009000521A1 (en) 2011-03-31
US20200157550A1 (en) 2020-05-21
EP2224005A1 (en) 2010-09-01
MX2009013609A (es) 2010-01-20
EP2224005B1 (en) 2013-09-11
US10544418B2 (en) 2020-01-28
AU2008263876B2 (en) 2012-04-12
JP2010530369A (ja) 2010-09-09
US11208662B2 (en) 2021-12-28
EA200901653A1 (ru) 2010-06-30
JP6193906B2 (ja) 2017-09-06
CA2690674C (en) 2018-09-11
SG10201404955RA (en) 2014-10-30
US7943592B2 (en) 2011-05-17
US20180148726A1 (en) 2018-05-31
US20100216971A1 (en) 2010-08-26
US20100210513A1 (en) 2010-08-19
EP2223693B1 (en) 2013-07-24
EP2223693A1 (en) 2010-09-01
ES2432158T3 (es) 2013-12-02
AR066984A1 (es) 2009-09-23
US20150284726A1 (en) 2015-10-08
US8119612B2 (en) 2012-02-21
US20160376599A1 (en) 2016-12-29
ES2432644T3 (es) 2013-12-04
EP2171059A2 (en) 2010-04-07
GT200900315A (es) 2011-10-05
TW201524510A (zh) 2015-07-01
CN101778941A (zh) 2010-07-14
CN101778941B (zh) 2013-05-22
EP2224004B1 (en) 2013-07-24
KR20160105530A (ko) 2016-09-06
KR101821081B1 (ko) 2018-01-23
EP2223695A1 (en) 2010-09-01
US20090156529A1 (en) 2009-06-18
JP7157775B2 (ja) 2022-10-20
US20220235361A1 (en) 2022-07-28
ECSP099794A (es) 2010-01-29
SG10201601846VA (en) 2016-04-28
TWI444474B (zh) 2014-07-11
JP2015145393A (ja) 2015-08-13
US20100210514A1 (en) 2010-08-19
EP2223694B1 (en) 2013-07-24
KR20100039335A (ko) 2010-04-15
US9476052B2 (en) 2016-10-25
WO2008152131A3 (en) 2009-05-28
BRPI0813680A2 (pt) 2015-01-06
US8168606B2 (en) 2012-05-01
EP2223694A1 (en) 2010-09-01
SG169988A1 (en) 2011-04-29
TWI552753B (zh) 2016-10-11

Similar Documents

Publication Publication Date Title
BRPI0813680A8 (pt) composição compreendendo um agente de irna para alfa-enac, constituído por um fita senso e uma fita antissenso, e seu uso
BRPI0921249A8 (pt) uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterápico na preparação de uma composição, e composições para o tratamento do cãncer
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BR112012008504A2 (pt) composição para entrega de agente ativo com carboidrato aprisionado e artigos usando a mesma
PT2124638T (pt) Composição de aperfeiçoamento de desempenho e utilização da mesma
BRPI0821636A2 (pt) Uso de um agente de mascaramento de sabor, composição líquida, e, uso da composição líquida
BRPI0911504A2 (pt) composição polimérica e uso da mesma, artigo com superfície granulada e uso de uma composição polimérica para a produção de um artigo
BRPI0816948A2 (pt) Composição fungicida para controlar fungos nocivos fitopatogênicos, agente fungicida, método para controlar fungos nocivos fitopatogênicos, semente, e, uso dos componentes
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0810022A2 (pt) Álcool alcoxilado, composição, e, uso de um álcool alcoxilado
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI0721438A2 (pt) Elemento absorvente para produtos de higiene sanitária, com bolsos expansíveis contendo material superabsorvente e processo de fabricação
BRPI0918359A2 (pt) composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto
BRPI0817200A2 (pt) composições oftálmicas sólida e uso de compostos para fabricação de medicamento
IL209062A (en) Annotations 2– (h1– pyrazole – 1 – yl) –3– (tetrahydro– h2– pyran – 4 – yl) propanamide Optional supplements with benzene and pyridine and their pharmaceutical preparations
BRPI0818804A2 (pt) Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
BRPI0719523A2 (pt) Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
BRPI0816182A2 (pt) Agente para promoção de adesão celular endotelial corneana
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BRPI0907365A2 (pt) Composição antimicrobiana e uso
BRPI0807220B1 (pt) composição, e, métodos para aumentar a força de compressão de uma composição e para aumentar a retenção de fragrância de uma composição
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI0920862A2 (pt) composição, método para fabricação da mesma, e uso da mesma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2831 DE 08-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.